TMCnet News
Highlight to present Phase 2 data at AACRHighlight Therapeutics to present data from Phase 2 immunotherapy studies of liver metastases and melanoma data at AACR Virtual Annual Meeting 2021 MADRID, Spain, April 14, 2021 (GLOBE NEWSWIRE) -- Highlight Therapeutics, (“Highlight”), a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, today announced that data from Phase 2 studies of its RNA-based immunotherapy BO-112 will be presented as posters at the American Association for Cancer Research (AACR) Virtual Annual Meeting 2021, April 10-15 and May 17-21. The e-poster presentations, which are available for browsing on from April 10, 2021, through June 21, 021, are entitled:
Click on, or paste the following link into your web browser, to view the associated PDF document. http://www.rns-pdf.londonstockexchange.com/rns/3658V_1-2021-4-13.pdf Contacts:
|